Actinogen Medical Limited Stock price

Equities

ACW

AU000000ACW3

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:09 2024-03-28 am EDT 5-day change 1st Jan Change
0.032 AUD +6.67% Intraday chart for Actinogen Medical Limited +14.29% +45.45%
Sales 2024 * 7.72M 5.03M Sales 2025 * 20.3M 13.22M Capitalization 74.6M 48.58M
Net income 2024 * -16M -10.42M Net income 2025 * -38M -24.75M EV / Sales 2024 * 9.9 x
Net Debt 2024 * 1.89M 1.23M Net Debt 2025 * 53.26M 34.69M EV / Sales 2025 * 6.3 x
P/E ratio 2024 *
-4 x
P/E ratio 2025 *
-2 x
Employees 6
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.04%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.67%
1 week+14.29%
Current month-3.03%
1 month-8.57%
3 months+52.38%
6 months+60.00%
Current year+45.45%
More quotes
1 week
0.03
Extreme 0.027
0.03
1 month
0.03
Extreme 0.027
0.04
Current year
0.02
Extreme 0.02
0.06
1 year
0.02
Extreme 0.015
0.07
3 years
0.02
Extreme 0.015
0.20
5 years
0.01
Extreme 0.007
0.20
10 years
0.01
Extreme 0.007
0.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 21-03-14
Director of Finance/CFO - Feb. 04
Chief Tech/Sci/R&D Officer - 22-03-31
Members of the board TitleAgeSince
Director/Board Member 73 17-11-30
Founder 68 99-03-22
Director/Board Member 68 19-04-03
More insiders
Date Price Change Volume
24-03-28 0.032 +6.67% 1,749,334
24-03-27 0.03 +5.26% 1,902,139
24-03-26 0.0285 +1.79% 1,487,637
24-03-25 0.028 -12.50% 2,672,013
24-03-22 0.032 +14.29% 2,759,496

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. It has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The Company conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Actinogen Medical Limited - Australian S.E.